Submission for OMB Review; Comment Request; Assessment of the Use of Special Funding for Research on Type 1 Diabetes Provided by the Balanced Budget Act of 1997, the FY 2001 Consolidated Appropriations Act, and the Public Health Service Act Amendment for Diabetes, 65907-65908 [05-21649]
Download as PDF
Federal Register / Vol. 70, No. 210 / Tuesday, November 1, 2005 / Notices
tobacco control as part of the National
Cancer Institute’s (NCI’s) Cancer
Progress Report, and the Department of
Health and Human Services’ Healthy
People 2010 Goals. It is also relevant to
past reports of NCI plans for the
National Investment in Cancer Research
and NCI’s long-term strategic plan for
eliminating the suffering and death due
to cancer. This survey is part of a
continuing series of surveys that were
sponsored by NCI and fielded
periodically over the 1990’s by the
Census Bureau as part of the American
Stop Smoking Intervention Study for
Cancer Prevention (ASSIST) project and
made available for general public use.
The Tobacco Use Supplements since
2001–02 have been fielded and will be
continuing over the next decade
alternating between a standard or core
tobacco use survey (such as this 2006–
2007 survey) and a special topic survey
focusing on emerging adult tobacco
control issues (such as the 2003 Tobacco
Use Special Cessation Supplement). The
survey will allow state specific
estimates to be made. Data will be
collected in May 2006, August 2006 and
January 2007 from approximately
65907
285,000 respondents. The National
Cancer Institute is co-sponsoring this
survey with the Centers for Disease
Control and Prevention.
Frequency of Response: One-time
study.
Affected Public: Individuals or
households.
Type of Respondents: Persons 15
years of age or older. The annual
reporting burden is presented in exhibit
1 below. There are no Capital Costs,
Operating Costs and/or Maintenance
Costs to report.
EXHIBIT 1.—ESTIMATES OF RESPONDENT HOUR BURDEN
Number of respondents
(number of annual respondents)
Frequency of
response
285,000 (95,000) .......................................................................................................................
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies should
address one or more of the following
points: (1) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) enhance the quality, utility and
clarity of the information to be
collected; and (4) minimize the burden
of the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
FOR FURTHER INFORMATION CONTACT:
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Anne Hartman,
M.S., M.A., Health Statistician, National
Cancer Institute, Executive Plaza
North—Suite 4005, 6130 Executive
Blvd., MSC 7344, Bethesda, Maryland
20892–7344, or call non-toll free (301)
496–4970, or fax your request to (301)
435–3710, or e-mail your request,
including your address, to
ah42t@nih.gov or
Anne_Hartman@nih.gov.
Comments Due Dates
Comments regarding this information
collection are best assured of having
VerDate Aug<31>2005
15:39 Oct 31, 2005
Jkt 208001
their full effect if received within 60
days of the date of this publication.
Dated: October 25, 2005.
Rachelle Ragland-Greene,
National Institutes of Health, NCI Project
Clearance Liaison.
[FR Doc. 05–21645 Filed 10–31–05; 8:45 am]
BILLING CODE 4101–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review;
Comment Request; Assessment of the
Use of Special Funding for Research
on Type 1 Diabetes Provided by the
Balanced Budget Act of 1997, the FY
2001 Consolidated Appropriations Act,
and the Public Health Service Act
Amendment for Diabetes
Summary: Under the provisions of
section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK), the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on March 10, 2005,
page 11994 and allowed 60 days for
public comment. No public comments
were received. The purpose of this
notice is to allow an additional 30 days
for public comment. The National
Institutes of Health may not conduct or
sponsor, the respondent is not required
to respond to, an information collection
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
Average burden hours per
response
1
0.1169
Total hour
burden (total
annual hour
burden)
33,317 (11,106)
that has been extended, revised, or
implemented on or after October 1,
1995, unless it displays a currently valid
OMB control number.
Proposed Collection
Title: Assessment of the Use of
Special Funding for Research on Type 1
Diabetes Provided by the Balanced
Budget Act of 1997, and the FY 2001
Consolidated Appropriations Act, and
the Public Health Service Act
Amendment for Diabetes. Type of
Information Collection Requested:
Revision, OMB control number: 0925–
0503; expiration date: 06/30/2005. Need
and Use of Information Collection: This
survey will be one source of input into
a statutorily mandated assessment and
report to the Congress on special
funding for research on type 1 diabetes
provided by the Balanced Budget Act of
1997, (Pub. L. 105–33), the FY 2001
Consolidated Appropriations Act, (Pub.
L. 106–554), and the Public Health
Service Act Amendment for Diabetes,
(Pub. L. 107–360). Collectively, these
Acts provided $1.14 billion in special
funds to the Department of Health and
Human Services (HHS) for research
aimed at understanding, treating, and
preventing type 1 diabetes and its
complications. The Secretary of HHS
subsequently designated to the NIDDK
the lead responsibility in the
Department for developing a process for
allocation of these funds. The primary
objective of this study is to gain
information, via a brief questionnaire,
from NIH research grantees who were
the primary recipients of these special
funds, concerning their views on the
impact of the type 1 diabetes research
E:\FR\FM\01NON1.SGM
01NON1
65908
Federal Register / Vol. 70, No. 210 / Tuesday, November 1, 2005 / Notices
fundings with respect to: (1) Advancing
scientific accomplishments involving
innovative, clinically relevant, and
multidisciplinary research on type 1
diabetes; (2) developing resources or
reagents useful for type 1 diabetes
research; and (3) increasing the number
and quality of type 1 diabetes
investigators. The responses will
provide valuable information
concerning how the funds have
facilitated research as intended by these
Acts of the Congress. The results will
also help determine how research
progress from these special
congressional initiatives fits within the
continuum of diabetes research, and
how these funds have contributed to the
field of type 1 diabetes research and
NIH efforts to combat this challenging
health problem. Information from this
study will aid in evaluation of the
process by which the research goals for
use of the special type 1 diabetes funds
have been developed and are being
pursued. Responses already collected
from this survey were analyzed as part
of an interim program assessment that
was published by the NIDDK in April,
2003 https://www.niddk.nih.gov/federal/
planning/type 1_specialfund/. This
revised survey will contribute to a
statutorily mandated report, due to the
Congress on January 1, 2007, evaluating
the process and efforts under this
program and assessing research
initiatives funded by these Act of
Congress. Frequency of Response: The
survey will require a one time response;
though, respondents may be contacted
again in the event of future
congressionally mandated reports on the
use of the special type 1 diabetes
research funds. Affected Public:
Research scientists who received the
special funds about which the Congress
has mandated in law the requirements
for an evaluation report. Type of
Respondents: Laboratory and clinical
investigators who have received support
from the special type 1 diabetes funds
provided under the laws previously
cited. The annual reporting burden is as
follows: Estimated number of
respondents: 500; Estimated Number of
Responses per Respondent: 1; Average
Burden Hours per Response: 1; and
Estimated Total Burden Hours
Requested: 500. The annualized total
cost to respondents is estimated at:
$25,000. It is expected that the
respondents will be contacted and will
return their responses via electronic
mail. These measures will reduce the
burden on the respondents and the
overall costs of administering the study.
Respondents will be asked to answer no
more than sixteen questions, one-third
VerDate Aug<31>2005
15:39 Oct 31, 2005
Jkt 208001
of which will be answered with ‘‘yes’’
or ‘‘no’’ or a one-word response. There
are no Capital Costs, Operating Costs or
Maintenance Costs to report.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Request For Comments
Office of Biotechnology Activities,
Office of Science Policy, Office of the
Director; Notice of Meeting
Written comments and/or suggestions
from the public and affected agencies
are invited on one or more of the
following points: (1) Whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions sued; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimize the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
Direct Comments to OMB
Written comments and/or suggestions
regarding the item(s) contained in this
notice, especially regarding the
estimated public burden and associated
response time, should be directed to the:
Office of Management and Budget,
Office of Regulatory Affairs, New
Executive Office Building, Room 10235,
Washington, DC 20503, Attention: Desk
Officer for NIH. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact: Dr.
Shefa Gordon, Presidential Management
Fellow, Office of Scientific Program and
Policy analysis, NIDDK, NIH, Building
31, Room 9A31, 9000 Rockville Pike,
Bethesda, MD 20892, or call non-tollfree number (301) 496–6623 or e-mail
your request, including your address, to:
gordonshefa@mail.nih.gov.
Comments Due Date
Comments regarding this information
collection are best assured of having
their full effect if received within 30
days of the date of this publication.
Dated: October 19, 2005.
Barbara Merchant,
Executive Officer, NIDDK.
[FR Doc. 05–21649 Filed 10–31–05; 8:45 am]
BILLING CODE 4140–01—M
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
National Institutes of Health
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the second meeting of
the National Science Advisory Board for
Biosecurity (NSABB).
Under authority 42 U.S.C. 217a,
Section 222 of the Public Health Service
Act, as amended, the Department of
Health and Human Services established
NSABB to provide advice, guidance and
leadership regarding federal oversight of
dual-use research, defined as biological
research with legitimate scientific
purposes that could be misused to pose
a biological threat to public health and/
or national security.
The meeting will be open to the
public, however, pre-registration is
strongly recommended due to space
limitations. Persons planning to attend
should register online at https://
www.biosecurityboard.gov/meetings.asp
or by calling The Hill Group (Contact:
A.J. Bownas) at 301–897–2789, ext. 100.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
indicate these requirements upon
registration.
Name of Committee: National Science
Advisory Board for Biosecurity.
Date: November 21, 2005.
Open: 9 a.m. to 6 p.m.
Agenda: Presentations and discussions
regarding: (1) Criteria for defining dual-use
research in the life sciences; (2) the role of
a code of conduct for the life sciences; (3)
communication of dual use research; (4)
international perspectives on dual use
research; (5) public comments; and (6) and
other business of the Board.
Place: The National Institutes of Health,
Building 31, 6C—Room 10, Bethesda,
Maryland.
Contact Person: Allison Chamberlain,
NSABB Program Assistant, 6705 Rockledge
Drive, Bethesda, Maryland 20892, (301) 402–
3090.
This meeting will also be webcast. The
draft meeting agenda and other information
about NSABB, including information about
access to the webcast and pre-registration,
will be available at https://
www.biosecurityboard.gov/meetings.asp.
Any member of the public interested in
presenting oral comments at the meeting may
notify the Contact Person listed on this notice
at least 10 days in advance of the meeting.
Interested individuals and representatives of
an organization may submit a letter of intent,
a brief description of the organization
E:\FR\FM\01NON1.SGM
01NON1
Agencies
[Federal Register Volume 70, Number 210 (Tuesday, November 1, 2005)]
[Notices]
[Pages 65907-65908]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-21649]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; Comment Request; Assessment of the Use
of Special Funding for Research on Type 1 Diabetes Provided by the
Balanced Budget Act of 1997, the FY 2001 Consolidated Appropriations
Act, and the Public Health Service Act Amendment for Diabetes
Summary: Under the provisions of section 3507(a)(1)(D) of the
Paperwork Reduction Act of 1995, the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK), the National Institutes of
Health (NIH) has submitted to the Office of Management and Budget (OMB)
a request for review and approval of the information collection listed
below. This proposed information collection was previously published in
the Federal Register on March 10, 2005, page 11994 and allowed 60 days
for public comment. No public comments were received. The purpose of
this notice is to allow an additional 30 days for public comment. The
National Institutes of Health may not conduct or sponsor, the
respondent is not required to respond to, an information collection
that has been extended, revised, or implemented on or after October 1,
1995, unless it displays a currently valid OMB control number.
Proposed Collection
Title: Assessment of the Use of Special Funding for Research on
Type 1 Diabetes Provided by the Balanced Budget Act of 1997, and the FY
2001 Consolidated Appropriations Act, and the Public Health Service Act
Amendment for Diabetes. Type of Information Collection Requested:
Revision, OMB control number: 0925-0503; expiration date: 06/30/2005.
Need and Use of Information Collection: This survey will be one source
of input into a statutorily mandated assessment and report to the
Congress on special funding for research on type 1 diabetes provided by
the Balanced Budget Act of 1997, (Pub. L. 105-33), the FY 2001
Consolidated Appropriations Act, (Pub. L. 106-554), and the Public
Health Service Act Amendment for Diabetes, (Pub. L. 107-360).
Collectively, these Acts provided $1.14 billion in special funds to the
Department of Health and Human Services (HHS) for research aimed at
understanding, treating, and preventing type 1 diabetes and its
complications. The Secretary of HHS subsequently designated to the
NIDDK the lead responsibility in the Department for developing a
process for allocation of these funds. The primary objective of this
study is to gain information, via a brief questionnaire, from NIH
research grantees who were the primary recipients of these special
funds, concerning their views on the impact of the type 1 diabetes
research
[[Page 65908]]
fundings with respect to: (1) Advancing scientific accomplishments
involving innovative, clinically relevant, and multidisciplinary
research on type 1 diabetes; (2) developing resources or reagents
useful for type 1 diabetes research; and (3) increasing the number and
quality of type 1 diabetes investigators. The responses will provide
valuable information concerning how the funds have facilitated research
as intended by these Acts of the Congress. The results will also help
determine how research progress from these special congressional
initiatives fits within the continuum of diabetes research, and how
these funds have contributed to the field of type 1 diabetes research
and NIH efforts to combat this challenging health problem. Information
from this study will aid in evaluation of the process by which the
research goals for use of the special type 1 diabetes funds have been
developed and are being pursued. Responses already collected from this
survey were analyzed as part of an interim program assessment that was
published by the NIDDK in April, 2003 https://www.niddk.nih.gov/federal/
planning/type 1--specialfund/. This revised survey will contribute to a
statutorily mandated report, due to the Congress on January 1, 2007,
evaluating the process and efforts under this program and assessing
research initiatives funded by these Act of Congress. Frequency of
Response: The survey will require a one time response; though,
respondents may be contacted again in the event of future
congressionally mandated reports on the use of the special type 1
diabetes research funds. Affected Public: Research scientists who
received the special funds about which the Congress has mandated in law
the requirements for an evaluation report. Type of Respondents:
Laboratory and clinical investigators who have received support from
the special type 1 diabetes funds provided under the laws previously
cited. The annual reporting burden is as follows: Estimated number of
respondents: 500; Estimated Number of Responses per Respondent: 1;
Average Burden Hours per Response: 1; and Estimated Total Burden Hours
Requested: 500. The annualized total cost to respondents is estimated
at: $25,000. It is expected that the respondents will be contacted and
will return their responses via electronic mail. These measures will
reduce the burden on the respondents and the overall costs of
administering the study. Respondents will be asked to answer no more
than sixteen questions, one-third of which will be answered with
``yes'' or ``no'' or a one-word response. There are no Capital Costs,
Operating Costs or Maintenance Costs to report.
Request For Comments
Written comments and/or suggestions from the public and affected
agencies are invited on one or more of the following points: (1)
Whether the proposed collection of information is necessary for the
proper performance of the function of the agency, including whether the
information will have practical utility; (2) The accuracy of the
agency's estimate of the burden of the proposed collection of
information, including the validity of the methodology and assumptions
sued; (3) Ways to enhance the quality, utility, and clarity of the
information to be collected; and (4) Ways to minimize the burden of the
collection of information on those who are to respond, including the
use of appropriate automated, electronic, mechanical, or other
technological collection techniques or other forms of information
technology.
Direct Comments to OMB
Written comments and/or suggestions regarding the item(s) contained
in this notice, especially regarding the estimated public burden and
associated response time, should be directed to the: Office of
Management and Budget, Office of Regulatory Affairs, New Executive
Office Building, Room 10235, Washington, DC 20503, Attention: Desk
Officer for NIH. To request more information on the proposed project or
to obtain a copy of the data collection plans and instruments, contact:
Dr. Shefa Gordon, Presidential Management Fellow, Office of Scientific
Program and Policy analysis, NIDDK, NIH, Building 31, Room 9A31, 9000
Rockville Pike, Bethesda, MD 20892, or call non-toll-free number (301)
496-6623 or e-mail your request, including your address, to:
gordonshefa@mail.nih.gov.
Comments Due Date
Comments regarding this information collection are best assured of
having their full effect if received within 30 days of the date of this
publication.
Dated: October 19, 2005.
Barbara Merchant,
Executive Officer, NIDDK.
[FR Doc. 05-21649 Filed 10-31-05; 8:45 am]
BILLING CODE 4140-01--M